Abbott Laboratories reported fourth-quarter revenue of $11.5 billion, missing consensus by $300 million primarily due to elevated manufacturing costs in its nutrition segment. Despite this shortfall, adjusted diluted earnings per share rose 12% year over year, in line with analyst forecasts. CEO Robert Ford has already initiated cost-reduction measures in nutrition and expects a return to positive growth by the second half of 2026. Given Abbott’s track record of operational resilience and its status as a Dividend King—marking 54 consecutive years of annual dividend increases—the nearly 10% share-price decline appears disproportionate to the underlying fundamentals.

Management has guided for 6.5% to 7.5% organic sales growth in 2026, up from 5.5% reported in 2025. At the midpoint, this implies roughly 10% adjusted EPS growth to approximately $5.68 per share. Abbott’s diversified portfolio spans medical devices, diagnostics, nutrition and established pharmaceuticals, with continuous innovation in areas such as continuous glucose monitoring and immunoassays. This breadth is a key defensive attribute, cushioning the business against isolated segment downturns and positioning it to capture market share in high-growth healthcare verticals.

Abbott expects to complete its acquisition of Exact Sciences in the second quarter of 2026, creating a new oncology diagnostics division focused on early cancer detection. This transaction is forecast to add a new multi-billion-dollar growth vertical, leveraging Exact’s leadership in colorectal and lung cancer screening tests. Management projects that synergies and cross-selling opportunities within Abbott’s distribution network will accelerate adoption, potentially contributing several hundred million dollars of incremental revenue by 2027 and further diversifying the company’s long-term growth profile.